Study Details

Back
Study ID 015K-CL-RA22
Study Title A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-finding, Multi-center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Patients
Clinicaltrials.gov Identifier NCT01565655
Compound Name ASP015K / peficitinib hydrobromide
Medical Indication or Disease Rheumatoid arthritis
Study Sponsor Astellas Pharma Global Development, Inc.
Collaborator Not Applicable
Study Start Date 19-Jun-2012
Study Completion Date 02-Dec-2013
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS